[go: up one dir, main page]

EA200970387A1 - Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения - Google Patents

Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения

Info

Publication number
EA200970387A1
EA200970387A1 EA200970387A EA200970387A EA200970387A1 EA 200970387 A1 EA200970387 A1 EA 200970387A1 EA 200970387 A EA200970387 A EA 200970387A EA 200970387 A EA200970387 A EA 200970387A EA 200970387 A1 EA200970387 A1 EA 200970387A1
Authority
EA
Eurasian Patent Office
Prior art keywords
deoxy
acetyl
beta
amino
salt
Prior art date
Application number
EA200970387A
Other languages
English (en)
Other versions
EA017005B1 (ru
Inventor
Дэвид Кучера
Грегори Дж. Хэйли
Эрик Дж. Руден
Тинминь Вань
Фритц Блаттер
Мартин Фиртельхаус
Original Assignee
Анадис Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анадис Фармасьютикалз, Инк. filed Critical Анадис Фармасьютикалз, Инк.
Publication of EA200970387A1 publication Critical patent/EA200970387A1/ru
Publication of EA017005B1 publication Critical patent/EA017005B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к соли п-толуолсульфокислоты 5-амино-3-(2'-О-ацетил-3'-дезокси-бета-D-рибофуранозил)-3Н-тиазоло[4,5-d]пиримидин-2-она и ее применению при лечении состояний, таких как вирусные инфекции, опухоли и злокачественные заболевания. Также раскрывается способ получения соли п-толуолсульфокислоты 5-амино-3-(2'-О-ацетил-3'-дезокси-бета-D-рибофуранозил)-3Н-тиазоло[4,5-d]пиримидин-2-она и способы получения производных фуранозы, которые являются пригодными промежуточными соединениями при получении фармацевтических соединений, таких как соль п-толуолсульфокислоты 5-амино-3-(2'-О-ацетил-3'-дезокси-бета-D-рибофуранозил)-3Н-тиазоло[4,5-d]пиримидин-2-она и тому подобное.
EA200970387A 2006-10-17 2007-10-16 СОЛЬ П-ТОЛУОЛСУЛЬФОКИСЛОТЫ 5-АМИНО-3-(2'-О-АЦЕТИЛ-3'-ДЕЗОКСИ-β-D-РИБОФУРАНОЗИЛ)-3Н-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-ОНА И СПОСОБЫ ПОЛУЧЕНИЯ EA017005B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
PCT/US2007/081526 WO2008140549A1 (en) 2006-10-17 2007-10-16 P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION

Publications (2)

Publication Number Publication Date
EA200970387A1 true EA200970387A1 (ru) 2009-10-30
EA017005B1 EA017005B1 (ru) 2012-09-28

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970387A EA017005B1 (ru) 2006-10-17 2007-10-16 СОЛЬ П-ТОЛУОЛСУЛЬФОКИСЛОТЫ 5-АМИНО-3-(2'-О-АЦЕТИЛ-3'-ДЕЗОКСИ-β-D-РИБОФУРАНОЗИЛ)-3Н-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-ОНА И СПОСОБЫ ПОЛУЧЕНИЯ

Country Status (24)

Country Link
US (2) US7928085B2 (ru)
EP (1) EP2076132B1 (ru)
JP (2) JP5279715B2 (ru)
KR (2) KR101486444B1 (ru)
AR (1) AR063484A1 (ru)
AU (1) AU2007353381B2 (ru)
BR (1) BRPI0717741A2 (ru)
CA (2) CA2898225A1 (ru)
CY (1) CY1113368T1 (ru)
DK (1) DK2076132T3 (ru)
DO (1) DOP2007000131A (ru)
EA (1) EA017005B1 (ru)
ES (1) ES2390930T3 (ru)
IL (2) IL198180A (ru)
MX (1) MX2009004028A (ru)
MY (1) MY150408A (ru)
NO (1) NO20091598L (ru)
NZ (1) NZ576408A (ru)
PE (1) PE20081105A1 (ru)
PL (1) PL2076132T3 (ru)
PT (1) PT2076132E (ru)
TW (1) TWI415854B (ru)
UY (1) UY30650A1 (ru)
WO (1) WO2008140549A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007260828B2 (en) 2006-06-22 2013-03-07 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-D-ribofuranosyl)-thiazolo[4,5-d] pyrimidin-2,7-dione
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
WO2016091698A1 (en) 2014-12-08 2016-06-16 F. Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CR20170424A (es) 2015-03-16 2018-01-26 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
WO2016180691A1 (en) 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
CN107592864B (zh) 2015-05-12 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
JP6839104B2 (ja) 2015-06-30 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
EP3568400A1 (en) * 2017-01-06 2019-11-20 H. Hoffnabb-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2-7-DIONE COMPOUNDS
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 １―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc ２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
EA008380B1 (ru) * 2001-11-27 2007-04-27 Анадис Фармасьютикалз, Инк. 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
KR20060096415A (ko) * 2003-09-05 2006-09-11 애나디스 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스에 의한 감염증을 치료하기 위해투여하는 ｔｌｒ７ 리간드 및 이의 전구약물
US20080070852A1 (en) * 2004-06-07 2008-03-20 Averett Devron R 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof
WO2006066080A1 (en) * 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
AU2007260828B2 (en) * 2006-06-22 2013-03-07 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-D-ribofuranosyl)-thiazolo[4,5-d] pyrimidin-2,7-dione
WO2008069303A1 (ja) * 2006-12-08 2008-06-12 Api Corporation フラノース誘導体の製造方法

Also Published As

Publication number Publication date
CA2666537A1 (en) 2008-11-20
IL223126A0 (en) 2012-12-31
PT2076132E (pt) 2012-10-03
IL223126A (en) 2016-08-31
KR20140119203A (ko) 2014-10-08
TW200833699A (en) 2008-08-16
EP2076132A1 (en) 2009-07-08
US8193342B2 (en) 2012-06-05
AU2007353381B2 (en) 2013-07-04
JP5703334B2 (ja) 2015-04-15
US7928085B2 (en) 2011-04-19
NZ576408A (en) 2012-04-27
AU2007353381A1 (en) 2008-11-20
US20090197826A1 (en) 2009-08-06
NO20091598L (no) 2009-07-10
DK2076132T3 (da) 2012-09-10
KR20090074237A (ko) 2009-07-06
JP2010506947A (ja) 2010-03-04
CA2666537C (en) 2015-12-08
MY150408A (en) 2014-01-15
MX2009004028A (es) 2009-05-11
DOP2007000131A (es) 2008-09-15
JP2013166782A (ja) 2013-08-29
ES2390930T3 (es) 2012-11-19
PE20081105A1 (es) 2008-08-15
BRPI0717741A2 (pt) 2014-04-08
EP2076132A4 (en) 2011-05-04
KR101486444B1 (ko) 2015-01-26
UY30650A1 (es) 2008-05-31
EP2076132B1 (en) 2012-07-11
CY1113368T1 (el) 2016-06-22
US20110172447A1 (en) 2011-07-14
CA2898225A1 (en) 2008-11-20
EA017005B1 (ru) 2012-09-28
HK1132429A1 (en) 2010-02-26
PL2076132T3 (pl) 2013-01-31
JP5279715B2 (ja) 2013-09-04
IL198180A (en) 2015-06-30
AR063484A1 (es) 2009-01-28
TWI415854B (zh) 2013-11-21
KR101515077B1 (ko) 2015-04-24
IL198180A0 (en) 2009-12-24
WO2008140549A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
EA200970387A1 (ru) Соль п-толуолсульфокислоты 5-амино-3-(2`-о-ацетил-3`-дезокси-бета-d-рибофуранозил)-3н-тиазоло[4,5-d]пиримидин-2-она и способы получения
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
ATE517882T1 (de) Chinolinderivate
JO2787B1 (en) Alternative amide derivatives and methods of use
ES2354824T3 (es) Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
EA201001159A1 (ru) Конденсированные гетероциклические производные и их применение
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
TW200606162A (en) Pyrazolopyridine derivatives
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM